VIDA
VIDA accelerates respiratory clinical trials and improves patient care through AI-powered lung intelligence solutions, offering precise quantitative endpoints, data quality controls, and site training.
Services
VIDA offers a range of services aimed at accelerating respiratory clinical trials. These include VIDA Discovery, which provides precise quantitative endpoints, AI-powered data quality controls, and site training. VIDA Insights helps physicians manage a variety of lung diseases, such as COPD, ILD, asthma, emphysema, lung cancer, and COVID-19. VIDA also delivers precision imaging analysis, trial orchestration via the VIDA Intelligence Portal, and comprehensive data intelligence services. Additionally, VIDA's subject screening services assist sponsors in filtering out candidates based on exclusion criteria, and their site performance monitoring services provide operational dashboards to track the health of clinical trial sites.
Products
VIDA's product offerings include VIDA Insights and VIDA Discovery, both of which hold regulatory clearances in the US, EU, Australia, and Canada. VIDA Insights is utilized by physicians for managing chronic respiratory conditions, while VIDA Discovery enables more efficient clinical trials. VIDA has also received 510(k) clearance for deep learning-based enhancements to its LungPrint® solution. Their AI-enabled biomarker services and retrospective data analysis services further enhance their portfolio, providing new insights from existing datasets.
History
VIDA has made significant strides in the field of respiratory clinical trials and lung disease management. The company has been involved in over 60 successful academic and industry clinical trials and has validated its solutions in over 200 studies. VIDA's network spans over 1,000 sites globally, and its AI-powered lung intelligence solutions are implemented across the UnityPoint Health system. Additionally, VIDA has expanded its global footprint to Japan through a partnership with Clairvo and has collaborated with Polarean to advance MRI technologies for lung imaging.
Sector
VIDA operates within the healthcare and medical technology sector, specifically focusing on respiratory clinical trials and lung disease management. The company leverages advanced AI technology to provide data quality controls, precision imaging analysis, and improved trial orchestration. VIDA's solutions are used to manage major lung diseases including COVID-19, asthma, COPD, ILD, lung cancer, and emphysema. Their services are HIPAA compliant and have received numerous regulatory clearances, positioning VIDA as a leader in lung intelligence and respiratory care.
Regulatory Clearances and Compliance
VIDA holds regulatory clearances for its VIDA Insights and VIDA Discovery solutions in the US, EU, Australia, and Canada. The company ensures compliance with HIPAA regulations, safeguarding patient data and maintaining high standards of privacy and security. These clearances and compliance measures validate VIDA's commitment to providing reliable and secure solutions for respiratory clinical trials and lung disease management.